2659 — Shanghai Bao Pharmaceuticals Share Price
Last trade - 00:00- HK$2.86bn
- HK$2.13bn
- CNY49.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.68 | ||
| Price to Tang. Book | 1.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 142.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.37% | ||
| Return on Equity | -31.3% | ||
| Operating Margin | -2108.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 6.93 | 6.16 | 49.16 | n/a | n/a | 166.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shanghai Bao Pharmaceuticals Co Ltd is a China-based company principally engaged in research and development of pharmaceutical products. The Company leverages synthetic biology technology to develop and deliver recombinant biologic drugs, targeting conditions with limited treatment options and complex manufacturing challenges. The Company focuses on four areas, including large-volume subcutaneous drug delivery, antibody-mediated autoimmune conditions, drugs in assisted reproduction and recombinant biologic products as transformative alternative to traditional biochemical production. The Company’s Core Products comprise SJ02 (Slonva), a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP), KJ017, a recombinant human hyaluronidase, and KJ103, an innovative recombinant immunoglobulin G (IgG)-degrading enzyme.
Directors
- Yanjun Liu CHM (60)
- Zheng Wang CEO (49)
- Jingwei Tan EDR (59)
- Cui Li CFO (39)
- Chia-Ling Lin NED (41)
- Juanhuan Diao NED (54)
- Chen Li NED (43)
- Zhongxi Cai NID (60)
- Yuhua Sun DGM (44)
- Juan Zheng NED
- Chun Ho TSANG SEC
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- December 16th, 2019
- Public Since
- December 10th, 2025
- No. of Employees
- 364
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 325,981,465
- Address
- No. 28, Luoxin Road, Baoshan District, SHANGHAI, 201908
- Web
- https://www.baopharma.com/
- Phone
- +86 2156696602
- Auditors
- Ernst & Young
Latest News for 2659
Upcoming Events for 2659
Similar to 2659
Abbisko Medicine
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 24:32 UTC, shares in Shanghai Bao Pharmaceuticals are trading at HK$8.78. This share price information is delayed by 15 minutes.
Shares in Shanghai Bao Pharmaceuticals last closed at HK$8.78 and the price had moved by over the past 365 days. In terms of relative price strength the Shanghai Bao Pharmaceuticals share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreShanghai Bao Pharmaceuticals does not currently pay a dividend.
Shanghai Bao Pharmaceuticals does not currently pay a dividend.
Shanghai Bao Pharmaceuticals does not currently pay a dividend.
To buy shares in Shanghai Bao Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$8.78, shares in Shanghai Bao Pharmaceuticals had a market capitalisation of HK$2.86bn.
Here are the trading details for Shanghai Bao Pharmaceuticals:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2659
Based on an overall assessment of its quality, value and momentum Shanghai Bao Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Bao Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -64.24%.
As of the last closing price of HK$8.78, shares in Shanghai Bao Pharmaceuticals were trading -82.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Bao Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$8.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shanghai Bao Pharmaceuticals' management team is headed by:
- Yanjun Liu - CHM
- Zheng Wang - CEO
- Jingwei Tan - EDR
- Cui Li - CFO
- Chia-Ling Lin - NED
- Juanhuan Diao - NED
- Chen Li - NED
- Zhongxi Cai - NID
- Yuhua Sun - DGM
- Juan Zheng - NED
- Chun Ho TSANG - SEC